Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin.
Data recorded by ECG, poly ECG, and echocardiography in 101 cancer patients treated with 4'-epi-doxorubicin are reported and compared with those previously obtained in a comparable group of 78 patients treated with doxorubicin. 4'-Epi-doxorubicin was administered by i.v. route in doses ranging from 50 to 90 mg/m2 in a three-weekly regimen; the maximum cumulative dose was 630 mg/m2. The results obtained demonstrate that this new antitumor anthracycline develops a lower acute cardiotoxic effect and suggest that 4'-epi-doxorubicin is endowed with a reduced chronic cardiotoxicity as compared to doxorubicin.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity*; D004452:Echocardiography; D004562:Electrocardiography; D015251:Epirubicin; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin